|
The combination biomarker could distinguish individuals with Alzheimer’s disease (AD) or a pre-AD stage (mild cognitive impairment, MCI) from normal controls with an AUC of 0.866 and 0.65, respectively.
Alzheimer's Disease diagnostics
Blood based biomarkers
Cost-effective compared to the leading diagnostic
Abstract
The inventors...
|